|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Massalou D, Benizri E, Chevallier A,
Duranton-Tanneur V, Pedeutour F, Benchimol D and Béréder JM:
Peritoneal carcinomatosis of colorectal cancer: Novel clinical and
molecular outcomes. Am J Surg. 213:377–387. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugarbaker PH: Colorectal cancer:
Prevention and management of metastatic disease. BioMed Res Int.
2014:7828902014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Segelman J, Granath F, Holm T, Machado M,
Mahteme H and Martling A: Incidence, prevalence and risk factors
for peritoneal carcinomatosis from colorectal cancer. Br J Surg.
99:699–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klaver YL, Simkens LH, Lemmens VE, Koopman
M, Teerenstra S, Bleichrodt RP, de Hingh IH and Punt CJ: Outcomes
of colorectal cancer patients with peritoneal carcinomatosis
treated with chemotherapy with and without targeted therapy. Eur J
Surg Oncol. 38:617–623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Franko J, Shi Q, Meyers JP, Maughan TS,
Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C,
et al: Prognosis of patients with peritoneal metastatic colorectal
cancer given systemic therapy: An analysis of individual patient
data from prospective randomised trials from the analysis and
research in cancers of the digestive system (ARCAD) database.
Lancet Oncol. 17:1709–1719. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fridman WH, Zitvogel L, Sautès-Fridman C
and Kroemer G: The immune contexture in cancer prognosis and
treatment. Nat Rev Clin Oncol. 14:717–734. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Keren L, Bosse M, Marquez D, Angoshtari R,
Jain S, Varma S, Yang SR, Kurian A, Van Valen D, West R, et al: A
Structured tumor-immune microenvironment in triple negative breast
cancer revealed by multiplexed ion beam imaging. Cell.
174:1373–1387.e19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peltanova B, Raudenska M and Masarik M:
Effect of tumor microenvironment on pathogenesis of the head and
neck squamous cell carcinoma: A systematic review. Mol Cancer.
18:632019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Veglia F, Perego M and Gabrilovich D:
Myeloid-derived suppressor cells coming of age. Nat Immunol.
19:108–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gabrilovich DI, Ostrand-Rosenberg S and
Bronte V: Coordinated regulation of myeloid cells by tumours. Nat
Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Otsubo D, Yamashita K, Fujita M, Nishi M,
Kimura Y, Hasegawa H, Suzuki S and Kakeji Y: Early-phase treatment
by Low-dose 5-Fluorouracil or primary tumor resection inhibits
MDSC-mediated lung metastasis formation. Anticancer Res.
35:4425–4431. 2015.PubMed/NCBI
|
|
14
|
Tanaka T, Fujita M, Hasegawa H, Arimoto A,
Nishi M, Fukuoka E, Sugita Y, Matsuda T, Sumi Y, Suzuki S, et al:
Frequency of Myeloid-derived suppressor cells in the peripheral
blood reflects the status of tumor recurrence. Anticancer Res.
37:3863–3869. 2017.PubMed/NCBI
|
|
15
|
Youn JI, Nagaraj S, Collazo M and
Gabrilovich DI: Subsets of Myeloid-Derived suppressor cells in
tumor bearing mice. J Immunol. 181:5791–5802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fortin C, Huang X and Yang Y: NK cell
response to vaccinia virus is regulated by myeloid-derived
suppressor cells. J Immunol. 189:1843–1849. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cassetta L, Baekkevold ES, Brandau S,
Bujko A, Cassatella MA, Dorhoi A, Krieg C, Lin A, Loré K, Marini O,
et al: Deciphering myeloid-derived suppressor cells: Isolation and
markers in humans, mice and non-human primates. Cancer Immunol
Immunother. 68:687–697. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Agresta L, Hoebe KHN and Janssen EM: The
emerging role of CD244 signaling in immune cells of the tumor
microenvironment. Front Immunol. 9:28092018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM,
Wang D, Li XF and Zheng L: Monocyte/macrophage-elicited natural
killer cell dysfunction in hepatocellular carcinoma is mediated by
CD48/2B4 interactions. Hepatology. 57:1107–1116. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wherry EJ and Kurachi M: Molecular and
cellular insights into T cell exhaustion. Nat Rev Immunol.
15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Youn JI, Collazo M, Shalova IN, Biswas SK
and Gabrilovich DI: Characterization of the nature of granulocytic
myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc
Biol. 91:167–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Clarke P, Mann J, Simpson JF,
Rickard-Dickson K and Primus FJ: Mice transgenic for human
carcinoembryonic antigen as a model for immunotherapy. Cancer Res.
58:1469–1477. 1998.PubMed/NCBI
|
|
23
|
Ojima T, Iwahashi M, Nakamura M, Matsuda
K, Nakamori M, Ueda K, Naka T, Ishida K, Primus FJ and Yamaue H:
Successful cancer vaccine therapy for carcinoembryonic antigen
(CEA)-expressing colon cancer using genetically modified dendritic
cells that express CEA and T helper-type 1 cytokines in CEA
transgenic mice. Int J Cancer. 120:585–593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kilkenny C, Browne WJ, Cuthill IC, Emerson
M and Altman DG: Improving bioscience research reporting: The
ARRIVE guidelines for reporting animal research. PLoS Biol.
8:e10004122010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feldman AT and Wolfe D: Tissue processing
and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arimoto A, Yamashita K, Hasegawa H, Sugita
Y, Fukuoka E, Tanaka T, Suzuki S and Kakeji Y: Immunosuppression
induced by perioperative peritonitis promotes lung metastasis.
Anticancer Res. 38:4333–4338. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bruger AM, Dorhoi A, Esendagli G,
Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T,
Santibanez J, Saraiva M, Van Ginderachter JA and Brandau S: How to
measure the immunosuppressive activity of MDSC: Assays, problems
and potential solutions. Cancer Immunol Immunother. 68:631–644.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shang W, Tang Z, Gao Y, Qi H, Su X, Zhang
Y and Yang R: LncRNA RNCR3 promotes Chop expression by sponging
miR-185-5p during MDSC differentiation. Oncotarget.
8:111754–111769. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schleicher U, Paduch K, Debus A, Obermeyer
S, König T, Kling JC, Ribechini E, Dudziak D, Mougiakakos D, Murray
PJ, et al: TNF-mediated restriction of arginase 1 expression in
myeloid cells triggers type 2 NO synthase activity at the site of
infection. Cell Rep. 15:1062–1075. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Agresta L, Lehn M, Lampe K, Cantrell R,
Hennies C, Szabo S, Wise-Draper T, Conforti L, Hoebe K and Janssen
EM: CD244 represents a new therapeutic target in head and neck
squamous cell carcinoma. J Immunother Cancer. 8:e0002452020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morris KT, Khan H, Ahmad A, Weston LL,
Nofchissey RA, Pinchuk IV and Beswick EJ: G-CSF and G-CSFR are
highly expressed in human gastric and colon cancers and promote
carcinoma cell proliferation and migration. Br J Cancer.
110:1211–1220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawano M, Mabuchi S, Matsumoto Y, Sasano
T, Takahashi R, Kuroda H, Kozasa K, Hashimoto K, Isobe A, Sawada K,
et al: The significance of G-CSF expression and myeloid-derived
suppressor cells in the chemoresistance of uterine cervical cancer.
Sci Rep. 5:182172015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pilatova K, Bencsikova B, Demlova R, Valik
D and Zdrazilova-Dubska L: Myeloid-derived suppressor cells (MDSCs)
in patients with solid tumors: Considerations for granulocyte
colony-stimulating factor treatment. Cancer Immunol Immunother.
67:1919–1929. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Veglia F, Sanseviero E and Gabrilovich DI:
Myeloid-derived suppressor cells in the era of increasing myeloid
cell diversity. Nat Rev Immunol. Feb 1–2021.(Epub ahead of print).
doi: 10.1038/s41577-020-00490-y. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ceelen W, Ramsay RG, Narasimhan V, Heriot
AG and De Wever O: Targeting the tumor microenvironment in
colorectal peritoneal metastases. Trends Cancer. 6:236–246. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Toyoshima M, Tanaka Y, Matumoto M,
Yamazaki M, Nagase S, Sugamura K and Yaegashi N: Generation of a
syngeneic mouse model to study the intraperitoneal dissemination of
ovarian cancer with in vivo luciferase imaging. Luminescence.
24:324–331. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Taibi A, Albouys J, Jacques J, Perrin ML,
Yardin C, Durand Fontanier S and Bardet SM: Comparison of
implantation sites for the development of peritoneal metastasis in
a colorectal cancer mouse model using non-invasive bioluminescence
imaging. PLoS One. 14:e02203602019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee YS, Lee WS, Kim CW, Lee SJ, Yang H,
Kong SJ, Ning J, Yang KM, Kang B, Kim WR, et al: Oncolytic vaccinia
virus reinvigorates peritoneal immunity and cooperates with immune
checkpoint inhibitor to suppress peritoneal carcinomatosis in colon
cancer. J Immunother Cancer. 8:e0008572020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cassim S and Pouyssegur J: Tumor
microenvironment: A metabolic player that shapes the immune
response. Int J Mol Sci. 21:1572019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Condamine T and Gabrilovich DI: Molecular
mechanisms regulating myeloid-derived suppressor cell
differentiation and function. Trends Immunol. 32:19–25. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Waight JD, Hu Q, Miller A, Liu S and
Abrams SI: Tumor-Derived G-CSF facilitates neoplastic growth
through a granulocytic myeloid-derived suppressor cell-dependent
mechanism. PLoS One. 6:e276902011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Weber R, Groth C, Lasser S, Arkhypov I,
Petrova V, Altevogt P, Utikal J and Umansky V: IL-6 as a major
regulator of MDSC activity and possible target for cancer
immunotherapy. Cell Immunol. 359:1042542021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kramer ED and Abrams SI: Granulocytic
myeloid-derived suppressor cells as negative regulators of
anticancer immunity. Front Immunol. 11:19632020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aapro MS, Cameron DA, Pettengell R,
Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen
VC, Walewski J, et al: EORTC guidelines for the use of
granulocyte-colony stimulating factor to reduce the incidence of
chemotherapy-induced febrile neutropenia in adult patients with
lymphomas and solid tumours. Eur J Cancer. 42:2433–2453. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Becker PS, Griffiths EA, Alwan LM,
Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks
A, et al: NCCN guidelines insights: Hematopoietic growth factors,
version 1.2020. J Natl Compr Canc Netw. 18:12–22. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lyman GH, Yau L, Nakov R and Krendyukov A:
Overall survival and risk of second malignancies with cancer
chemotherapy and G-CSF support. Ann Oncol. 29:1903–1910. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fan Z, Li Y, Zhao Q, Fan L, Tan B, Zuo J,
Hua K and Ji Q: Highly expressed granulocyte colony-stimulating
factor (G-CSF) and granulocyte colony-stimulating factor receptor
(G-CSFR) in human gastric cancer leads to poor survival. Med Sci
Monit. 24:1701–1711. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Moses K, Klein JC, Männ L, Klingberg A,
Gunzer M and Brandau S: Survival of residual neutrophils and
accelerated myelopoiesis limit the efficacy of antibody-mediated
depletion of Ly-6G+ cells in tumor-bearing mice. J
Leukoc Biol. 99:811–823. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Law AM, Valdes-Mora F and Gallego-Ortega
D: Myeloid-derived suppressor cells as a therapeutic target for
cancer. Cells. 9:5612020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vetsika EK, Koukos A and Kotsakis A:
Myeloid-Derived suppressor cells: Major figures that shape the
immunosuppressive and angiogenic network in cancer. Cells.
8:16472019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Coffelt SB, Wellenstein MD and de Visser
KE: Neutrophils in cancer: Neutral no more. Nature Reviews Cancer.
16:431–446. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Steele CW, Karim SA, Leach JDG, Bailey P,
Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z,
et al: CXCR2 inhibition profoundly suppresses metastases and
augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer
Cell. 29:832–845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sun L, Clavijo PE, Robbins Y, Patel P,
Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, et al:
Inhibiting myeloid-derived suppressor cell trafficking enhances T
cell immunotherapy. JCI Insight. 4:e1268532019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kurachi M: CD8+ T cell
exhaustion. Semin Immunopathol. 41:327–337. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Martinez M and Moon EK: CAR T cells for
solid tumors: New strategies for finding, infiltrating, and
surviving in the tumor microenvironment. Front Immunol. 10:1282019.
View Article : Google Scholar : PubMed/NCBI
|
